Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD59, also known as Membrane Inhibitor of Reactive Lysis (MIRL), MAC-inhibitory protein (MAC-IP), or protectin, is a glycoprotein that inhibits the formation of the complement membrane attack complex (MAC), protecting cells from complement-mediated lysis. It is implicated in diseases such as Paroxysmal Nocturnal Hemoglobinuria (PNH) and is explored as an immunotherapeutic target in cancer.
Binds to complement components C8 and/or C9, preventing C9 polymerization and MAC formation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD59 molecule (CD59).